These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 29678900)
21. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242 [TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis. Wang D; Fu W; Dai J Medicine (Baltimore); 2019 Apr; 98(17):e15285. PubMed ID: 31027086 [TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients. Wang S; Zhang A; Yao X Intern Med J; 2021 Sep; 51(9):1505-1512. PubMed ID: 33469994 [TBL] [Abstract][Full Text] [Related]
24. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials. Zhuo GY; He Q; Xiang-Lian L; Ya-Nan Y; Si-Te F Pulm Pharmacol Ther; 2014 Oct; 29(1):80-8. PubMed ID: 24594263 [TBL] [Abstract][Full Text] [Related]
25. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Gao YH; Guan WJ; Xu G; Tang Y; Gao Y; Lin ZY; Lin ZM; Zhong NS; Chen RC PLoS One; 2014; 9(3):e90047. PubMed ID: 24603554 [TBL] [Abstract][Full Text] [Related]
30. Inhaled hyperosmolar agents for bronchiectasis. Hart A; Sugumar K; Milan SJ; Fowler SJ; Crossingham I Cochrane Database Syst Rev; 2014 May; 2014(5):CD002996. PubMed ID: 24817558 [TBL] [Abstract][Full Text] [Related]
31. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Herath SC; Poole P Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145 [TBL] [Abstract][Full Text] [Related]
32. Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations. Kapur N; Masters IB; Chang AB Respir Med; 2009 Nov; 103(11):1681-7. PubMed ID: 19501498 [TBL] [Abstract][Full Text] [Related]
33. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. Valery PC; Morris PS; Grimwood K; Torzillo PJ; Byrnes CA; Masters IB; Bauert PA; McCallum GB; Mobberly C; Chang AB BMC Pediatr; 2012 Aug; 12():122. PubMed ID: 22891748 [TBL] [Abstract][Full Text] [Related]
34. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? King P Drugs; 2007; 67(7):965-74. PubMed ID: 17488142 [TBL] [Abstract][Full Text] [Related]
35. [Inhaled antibiotics in the treatment of noncystic fibrosis bronchiectasis]. Martínez García MÁ; Soler Cataluña JJ; Serra PC Arch Bronconeumol; 2011 Jun; 47 Suppl 6():19-23. PubMed ID: 21703475 [TBL] [Abstract][Full Text] [Related]
37. Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis. Lee E; Sol IS; Kim JD; Yang HJ; Min TK; Jang GC; Hwang YH; Cho HJ; Suh DI; Kim K; Kim HS; Kim YH; Woo SI; Lee YJ; Jung S; Jeon YH Sci Rep; 2021 Dec; 11(1):24287. PubMed ID: 34930997 [TBL] [Abstract][Full Text] [Related]
38. Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under. Onakpoya IJ; Hayward G; Heneghan CJ Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011530. PubMed ID: 26408070 [TBL] [Abstract][Full Text] [Related]
39. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]